| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 341.24% |
Twist Bioscience (TWST) | 2026 | 312.86% |
Immunitybio (IBRX) | 2026 | 293.56% |
Aehr Test Systems (AEHR) | 2026 | 281.73% |
Pulse Biosciences (PLSE) | 2026 | 280.91% |
Enliven Therapeutics (ELVN) | 2026 | 280.71% |
10X Genomics (TXG) | 2026 | 277.99% |
MaxLinear (MXL) | 2026 | 237.07% |
Abcellera Biologics (ABCL) | 2026 | 232.16% |
AXT (AXTI) | 2026 | 231.1% |
Maase (MAAS) | 2026 | 222.22% |
Hyperliquid Strategies Inc Common Stock (PURR) | 2026 | 220.68% |
Sellas Life Sciences (SLS) | 2026 | 218.2% |
Iovance Biotherapeutics (IOVA) | 2026 | 210.07% |
Oruka Therapeutics (ORKA) | 2026 | 202.31% |
Veradermics (MANE) | 2026 | 189.59% |
Definium Therapeutics (DFTX) | 2026 | 188.15% |
Amylyx Pharmaceuticals (AMLX) | 2026 | 187.42% |
Applied Opt (AAOI) | 2026 | 183.75% |
PBF Energy (PBF) | 2026 | 181.28% |
Iridium Communications (IRDM) | 2026 | 170.58% |
Calumet Specialty Products Partners (CLMT) | 2026 | 168.44% |
Spyre Therapeutics (SYRE) | 2026 | 165.72% |
CareDx (CDNA) | 2026 | 163.27% |
Silicon Motion Technology (SIMO) | 2026 | 158.52% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.